Clinical relevance of the urokinase plasminogen activator system in breast cancer

Until recently clinical features and the hormone‐receptor status were the only factors used to select systemic (adjuvant) treatment for breast cancer patients. Other biological factors are needed as well to predict the probability of relapse and response with more certainty. The uPA‐system is such a prognostic and predictive factor in breast cancer. In this review, the results of research groups that have related relapse‐free survival to the quantitative levels of uPA‐system proteins and/or activities are discussed. Only studies that described the results from assays on cytosols or triton extracts of breast tumours were included. The levels of uPA‐system proteins help to predict the probability of relapse and response, and knowledge of the expression levels of the various components of the uPA‐system may lead to new treatment modalities targeted on specific properties of the uPA‐system.

[1]  M. Duffy,et al.  Urokinase Plasminogen Activator: a Prognostic Marker in Breast Cancer including Patients with Axillary Node-negative Disease Materials and Methods Methods Enzymes and Protein Markers , 1997 .

[2]  H. Höfler,et al.  Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. , 1998, Anticancer research.

[3]  F. Spyratos,et al.  Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods. , 1998, British Journal of Cancer.

[4]  A. Laenkholm,et al.  Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. , 1998, British Journal of Cancer.

[5]  H. Koyama,et al.  Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  G. Huet,et al.  Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  T. Taguchi,et al.  A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue , 1997, Journal of Cancer Research and Clinical Oncology.

[8]  H. Chapman,et al.  Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. , 1997, Current opinion in cell biology.

[9]  D. Wallwiener,et al.  Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. , 1997, British Journal of Cancer.

[10]  M. Duffy,et al.  Plasminogen activator inhibitor type 2 in breast cancer. , 1997, British Journal of Cancer.

[11]  N. Harbeck,et al.  Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. , 1997, British Journal of Cancer.

[12]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[13]  H. Höfler,et al.  Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.

[14]  N. Brünner,et al.  Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  N. Brünner,et al.  Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. , 1996, European journal of cancer.

[16]  M. Fernö,et al.  Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. , 1996, European journal of cancer.

[17]  M. Duffy,et al.  Proteases as prognostic markers in cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  M. Duffy,et al.  Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. , 1996, Enzyme & protein.

[19]  N. Brünner,et al.  Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  M. Ogawa,et al.  Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. , 1995, Surgery.

[21]  F. Blasi,et al.  The urokinase/urokinase-receptor system and cancer invasion. , 1995, Bailliere's clinical haematology.

[22]  M. Duffy,et al.  Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer , 1995, International journal of cancer.

[23]  J. Foekens,et al.  Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. , 1995, Journal of the National Cancer Institute.

[24]  J. Foekens,et al.  Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. , 1995, Cancer research.

[25]  M. Duffy,et al.  Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer , 1994, Cancer.

[26]  J. Foekens,et al.  Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  K. Ulm,et al.  Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. , 1994, Cancer research.

[28]  F. Spyratos,et al.  Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. , 1994, British Journal of Cancer.

[29]  N. Brünner,et al.  Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer. , 1994, Cancer treatment and research.

[30]  M. Schmitt,et al.  Prospects in diagnosis and treatment of breast cancer : proceedings of the Joint International Symposium on Prospects in Diagnosis and Treatment of Breast Cancer, 10-11 November 1993, Munich, Germany , 1994 .

[31]  M. Ogawa,et al.  Industrial preparation of poly(vinyl chloride). , 1975, British Journal of Cancer.

[32]  N. Brünner,et al.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. , 1993, Cancer research.

[33]  C. Belluco,et al.  Prognostic factors in node-negative breast cancer. , 1992, Archives of surgery.

[34]  J. Foekens,et al.  Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.

[35]  F. Spyratos,et al.  Multiparametric prognostic evaluation of biological factors in primary breast cancer. , 1992, Journal of the National Cancer Institute.

[36]  M. Duffy,et al.  Type‐1 plasminogen activator inhibitor in human breast carcinomas , 1992, International journal of cancer.

[37]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[38]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[39]  Earlybreastcancertrialistscol,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[40]  A. Desplaces,et al.  Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. , 1991, British Journal of Cancer.

[41]  F. Jänicke,et al.  Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer , 1991, Seminars in thrombosis and hemostasis.

[42]  M. Duffy,et al.  Urokinase‐plasminogen activator in breast cancer: assay by both catalytic and immunoassay , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[43]  M. Duffy,et al.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. , 1990, Cancer research.

[44]  K. Ulm,et al.  Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer , 1990 .

[45]  M. Duffy,et al.  Urokinase plasminogen activator and prognosis in breast cancer , 1990, The Lancet.

[46]  M. Schmitt,et al.  UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTIGEN AND EARLY RELAPSE IN BREAST CANCER , 1989, The Lancet.

[47]  M. Duffy,et al.  Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.

[48]  N. N. Aleksandrov,et al.  [Diagnosis and treatment of breast cancer]. , 1978, Voprosy onkologii.